Literature DB >> 32436563

Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.

Sanghyuk S Shin1, Chawangwa Modongo2,3, Nicola M Zetola2.   

Abstract

Entities:  

Keywords:  HIV and tuberculosis coinfection; dolutegravir dosage; pharmacokinetics; tuberculosis treatment outcome; virological outcome

Mesh：

Substances：

Year:  2020        PMID： 32436563      PMCID： PMC7312218          DOI： 10.1093/cid/ciz917

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.

Authors:  Chawangwa Modongo; Qiao Wang; Mbatshi Dima; Ogopotse Matsiri; Botshelo Kgwaadira; Goabaone Rankgoane-Pono; Sanghyuk S Shin; Nicola M Zetola
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

2.  Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.

Authors:  Xinzhu Wang; Maddalena Cerrone; Francesca Ferretti; Nadia Castrillo; Gary Maartens; Myra McClure; Marta Boffito
Journal:  Int J Antimicrob Agents       Date:  2019-04-16       Impact factor: 5.283

3.  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Authors:  Kelly E Dooley; Patrick Sayre; Julie Borland; Elizabeth Purdy; Shuguang Chen; Ivy Song; Amanda Peppercorn; Stephanie Everts; Stephen Piscitelli; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

Review 4.  Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.

Authors:  Kelly E Dooley; Debra Hanna; Vidya Mave; Kathleen Eisenach; Radojka M Savic
Journal:  PLoS Med       Date:  2019-07-05       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.